Recent advances in omics technologies have led to unprecedented efforts characterizing
the molecular changes that underlie the development and progression of a wide array of …

Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

PURPOSE To provide recommendations on genetic and tumor testing for women diagnosed
with epithelial ovarian cancer based on available evidence and expert consensus …

Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers
(HGSCs) survive more than five years after diagnosis, but those who have an exceptionally …

DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor
DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic …

Epithelial ovarian cancer (EOC) is one of the cancers most influenced by hereditary factors.
A fourth to a fifth of unselected EOC patients carry pathogenic variants (PVs) in a number of …

The Cancer Genome Atlas (TCGA) is a public funded project that aims to catalogue and
discover major cancer-causing genomic alterations to create a comprehensive “atlas” of …

Epithelial ovarian cancer (EOC) represents a heterogeneous spectrum of disease entities at
a clinical, pathological and molecular level. Ovarian cancer is the second most lethal …

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …